Pedro J Cejas

Pedro J Cejas serves as the Head of New Therapeutic Modalities at Spark Therapeutics, Inc. since September 2020, having previously held multiple leadership roles in discovery research. Prior experience at Merck (February 2012 - September 2020) includes co-leading a basic discovery/preclinical mRNA vaccine program against RSV and engaging in infectious disease vaccine and therapeutic development. Prior to Merck, Pedro J Cejas conducted postdoctoral research at the University of Pennsylvania, focusing on immune cell biology. Academic credentials include a Ph.D. in Microbiology and Immunology from the University of Miami and a B.S. in Chemistry from the University of Havana, complemented by participation in the Merck Business Leadership Program.